Gå till Affärer
Hälsovård

Dimainvest S.r.l. has launched a voluntary public tender offer for Shedir Pharma Group S.p.A.

Dimainvest S.r.l. has initiated a voluntary public tender offer for the shares of Shedir Pharma Group S.p.A.

Dimainvest is a holding company owned by Umberto Di Maio, the controlling shareholder of Shedir Pharma Group.

Shedir Pharma Group manufactures and distributes nutraceuticals, cosmetics and medical devices. The company is headquartered in Piano di Sorrento, Italy.

Oaklins Italy’s parent company, Banca Akros, acted as the appointed broker for the collection of shares in the voluntary public tender offer for 11.9% of Shedir Pharma Group’s shares by Dimainvest.

Parter

Prata med transaktionsteamet

Giulio Greco

Managing Director
Milano, Italien
Oaklins Italy

Nicola Vulcano

Director
Milano, Italien
Oaklins Italy

Marco Valsecchi

Associate
Milano, Italien
Oaklins Italy

Rita Vizzi

Analyst
Milano, Italien
Oaklins Italy

Relaterade affärer

Backspin has completed a mandatory public tender offer for the shares of Spindox
Riskkapital | TMT

Backspin has completed a mandatory public tender offer for the shares of Spindox

Backspin S.p.A. has completed a mandatory public tender offer for Spindox S.p.A.

Lär dig mer
Rare Patient Voice has been acquired by Konovo
Hälsovård | TMT

Rare Patient Voice has been acquired by Konovo

Rare Patient Voice has been acquired by Konovo, a technology-first healthcare intelligence company backed by Fraser Healthcare Partners.

Lär dig mer
Lindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland
Hälsovård

Lindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland

LabPoint Medical Laboratories AG has been acquired by Affidea Switzerland AG. Through the transaction, Lindenhofgruppe AG gains a strong strategic partner to support the further development of LabPoint and will remain a shareholder with a reduced stake, continuing as a key customer of the company. It lays the foundation for LabPoint’s sustainable development under a new anchor shareholder, with the aim of further strengthening and selectively expanding its position in laboratory diagnostics.

Lär dig mer